Webinar Replay

Disentangling Common Vaginal Infections with Rapid Point-of-Care Testing

You already have access to this webinar replay.

Please complete the following to have access to the full webinar:

Personal data is neither shared with nor sold to third parties; review here the Visby Medical Privacy Statement.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Video replay image


Dr. Christina Muzny

Christina Muzny, MD, MSPH, FACP, FIDSA
University of Alabama at Birmingham


Trichomoniasis, the most common non-viral sexually transmitted infection, is underdiagnosed due to lack of screening, surveillance, and control programs. The most commonly used diagnostic test lacks sensitivity. Undertreating trichomoniasis can lead to adverse health outcomes and persistence of infection in sexual networks. This webinar evaluates a modern approach to managing this neglected disease.

Learning Objectives

In this video, participants will:

  • Distinguish between BV and trichomoniasis in terms of epidemiology, pathogenesis, and adverse health outcomes
  • Recognize clinical symptoms associated with both vaginal infections
  • Discuss traditional and novel diagnostic methods for BV and trichomoniasis
  • Illustrate how point-of-care testing could accurately and rapidly diagnose trichomoniasis

Access Includes:

  • Video recording replay
  • Presentation Slides (PDF)

About the Presenter

Dr. Christina Muzny

Dr. Christina Muzny is a tenured Associate Professor in the Division of Infectious Diseases at the University of Alabama (UAB) with a secondary appointment in the Department of Epidemiology. She is a medical consultant for the 2021 CDC STI Treatment Guidelines, a teaching faculty for the Alabama-North Carolina STD/HIV Prevention Training Center and an Associate Scientist for the UAB Center for AIDS Research. Her clinical and research interests focus on the epidemiology, diagnosis, and treatment of HIV and sexually transmitted infections, specifically vaginal infections. Muzny has R01 and R21 funding from NIH/NIAID to study the pathogenesis of BV and has participated in clinical trials regarding use of 5-nitroimidazoles and secnidazole for the treatment of trichomoniasis.